Search results
Study shows CAR NK cells with CD28 costimulation improve cell persistence and antitumor activity
Medical Xpress· 3 days agoAdding CD28 costimulation to cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cells targeting CD70+ cancers significantly enhanced antitumor efficacy ...
Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with...
Morningstar· 6 days agoApplication based on Phase 3 PALOMA-3 results showing five-fold reduction in infusion-related reactions with five-minute administration of subcutaneous amivantamab Longer overall survival, progression-free ...
Children genetically prone to cancer benefit from | Newswise
Newswise· 4 days agoAlthough genetic predispositions increase the risk for new tumors, it has been unclear when to begin...
Charles River and Captain T Cell sign vector production agreement
Pharmaceutical Technology via Yahoo Finance· 6 days agoThe T cells seek out and eliminate tumour cells, potentially offering a new therapeutic avenue for...
Fate Therapeutics stock upgraded by Piper Sandler on autoimmune focus By Investing.com
Investing.com· 7 days agoThe biopharmaceutical company, known for its work in developing programmed cell therapies for cancer...
Day One (DAWN) In-Licenses MabCare Cancer Candidate, Stock Up
Zacks via Yahoo Finance· 4 days agoDay One (DAWN) gains 11% on in-licensing exclusive worldwide rights to MabCare???s MTX-13, which is...
Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold
Zacks via Yahoo Finance· 4 days agoZentalis' (ZNTL) three studies evaluating azenosertib for three different cancer indications face...
Johnson & Johnson submits BLA to FDA for lung cancer drug
Pharmaceutical Technology via Yahoo Finance· 6 days agoJohnson & Johnson innovative medicine solid tumours clinical development vice-president Kiran Patel...
Rockville cancer therapy company set to IPO this week - Washington Business Journal
The Business Journals· 5 days agoOS Therapies Inc., a Rockville biotech advancing a treatment for a rare cancer plaguing kids, is...
...cema-cel), an Allogeneic CAR T Product, as Part of First LineTreatment for Patients with Large...
Morningstar· 3 days agoALPHA3 Trial Has the Potential to Position Cema-cel as Part of First Line (1L) Treatment for LBCL to Improve Cure RatesFirst Prospective Trial to Incorporate the Foresight ...